Research analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a report released on Wednesday. The firm set a “hold” rating on the stock. Trinity ...
Hosted on MSN1mon
Trinity Biotech announces breakthrough in CGM technologyTrinity Biotech is now poised to pursue further clinical trials and aims to file for regulatory approval in the European Union in 2025, followed by U.S. FDA approval in 2026.
Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.
Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...
DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...
(RTTNews) - Trinity Biotech plc (TRIB), a biotechnology company focused on diabetes management, on Thursday announced notable advances in its pre-pivotal trial for its next-generation continuous ...
Shares of Trinity Biotech (NASDAQ:TRIB) traded sharply higher on Tuesday after the Irish MedTech reported encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose ...
Trinity Biotech (TRIB) announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance for its next-generation continuous glucose ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results